{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:54:03Z","timestamp":1790952843434,"version":"4.1.0"},"reference-count":72,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:p>Proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors are a key component of lipid-lowering therapies for atherosclerotic cardiovascular disease risk management in high-risk primary and secondary prevention populations. PCSK9 monoclonal antibodies such as evolocumab and alirocumab were the first agents approved and are the preferred agents, given the phase 3 trial data supporting improved cardiovascular outcomes. Subgroup analyses of these trials have highlighted high-risk populations that may especially benefit from PCSK9 inhibitor therapy, although demographic disparities persist regarding their implementation. Additional injectable agents with less-frequent dosing schedules have been developed, such as the small-interfering RNA inclisiran, although they lack data regarding cardiovascular outcomes. Oral agents are also in development, with promising data recently presented regarding enlicitide. In addition, recent trials provide evidence supporting expanded indications for high-risk primary prevention. This review summarizes currently available and investigational PCSK9-targed therapies and examines evidence guiding their clinical implementation.<\/jats:p>","DOI":"10.1097\/fjc.0000000000001852","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T18:01:37Z","timestamp":1783015297000},"page":"308-316","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["A Comprehensive Review of PCSK9 Inhibitor Therapy"],"prefix":"10.1097","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-6994-2551","authenticated-orcid":false,"given":"Madelyn","family":"Hurwitz","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anandita","family":"Kulkarni","sequence":"additional","affiliation":[{"name":"Baylor Scott and White Health: The Heart Hospital Plano, Plano, TX; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francoise A.","family":"Marvel","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaideep","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261002","first-page":"1129","article-title":"2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol."},{"key":"R2-20261002","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","article-title":"2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk","volume":"80","author":"Lloyd-Jones","year":"2022","journal-title":"J Am Coll Cardiol."},{"key":"R3-20261002","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1016\/j.jacc.2024.03.382","article-title":"An \u201cInclisiran First\u201d strategy vs usual care in patients with atherosclerotic cardiovascular disease","volume":"83","author":"Koren","year":"2024","journal-title":"J Am Coll Cardiol."},{"key":"R4-20261002","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study","volume":"28","author":"Ray","year":"2021","journal-title":"Eur J Prev Cardiol."},{"key":"R5-20261002","doi-asserted-by":"crossref","first-page":"100624","DOI":"10.1016\/j.lanepe.2023.100624","article-title":"Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study","volume":"29","author":"Ray","year":"2023","journal-title":"Lancet Reg Health Eur."},{"key":"R6-20261002","doi-asserted-by":"crossref","first-page":"100336","DOI":"10.1016\/j.ajpc.2022.100336","article-title":"Lipid treatment status and goal attainment among patients with atherosclerotic cardiovascular disease in the United States: a 2019 update","volume":"10","author":"Gu","year":"2022","journal-title":"Am J Prev Cardiol."},{"key":"R7-20261002","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1080\/00325481.2022.2117498","article-title":"LDL-C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goals","volume":"134","author":"Underberg","year":"2022","journal-title":"Postgrad Med."},{"key":"R8-20261002","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.15420\/usc.2024.33","article-title":"Strategies for the secondary prevention of atherosclerotic cardiovascular disease","volume":"19","author":"Hurwitz","year":"2025","journal-title":"US Cardiol."},{"key":"R9-20261002","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000001457","article-title":"2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice Guidelines","volume":"153","author":"Blumenthal","year":"2026","journal-title":"Circulation"},{"key":"R10-20261002","first-page":"e1082","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"R11-20261002","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on clinical practice guidelines","volume":"148","author":"Virani","year":"2023","journal-title":"Circulation"},{"key":"R12-20261002","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J."},{"key":"R13-20261002","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J."},{"key":"R14-20261002","doi-asserted-by":"crossref","first-page":"101314","DOI":"10.1016\/j.ajpc.2025.101314","article-title":"The discovery of PCSK9 as a pivotal point in the prevention of cardiovascular disease","volume":"24","author":"Razavi","year":"2025","journal-title":"Am J Prev Cardiol."},{"key":"R15-20261002","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med."},{"key":"R16-20261002","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med."},{"key":"R17-20261002","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2514428","article-title":"Evolocumab in patients without a previous myocardial infarction or stroke","volume":"394","author":"Bohula","year":"2026","journal-title":"N Engl J Med."},{"key":"R18-20261002","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med."},{"key":"R21-20261002","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1001\/jamacardio.2024.1659","article-title":"Efficacy and safety of lerodalcibep in patients with or at high risk of cardiovascular disease: a randomized clinical trial","volume":"9","author":"Klug","year":"2024","journal-title":"JAMA Cardiol."},{"key":"R22-20261002","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med."},{"key":"R23-20261002","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","article-title":"Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial","volume":"5","author":"Sabatine","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"R24-20261002","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/S2213-8587(19)30158-5","article-title":"Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial","volume":"7","author":"Ray","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"R25-20261002","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.122.061620","article-title":"Long-term evolocumab in patients with established atherosclerotic cardiovascular disease","volume":"146","author":"O'Donoghue","year":"2022","journal-title":"Circulation"},{"key":"R26-20261002","doi-asserted-by":"crossref","first-page":"e029216","DOI":"10.1161\/JAHA.122.029216","article-title":"Long\u2010term efficacy, safety, and tolerability of alirocumab in 8242 patients eligible for 3 to 5 years of placebo\u2010controlled observation in the ODYSSEY OUTCOMES trial","volume":"12","author":"Goodman","year":"2023","journal-title":"J Am Heart Assoc."},{"key":"R27-20261002","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1016\/j.jacc.2020.03.039","article-title":"Cognition after lowering LDL-cholesterol with Evolocumab","volume":"75","author":"Gencer","year":"2020","journal-title":"J Am Coll Cardiol."},{"key":"R28-20261002","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1701131","article-title":"Cognitive function in a randomized trial of evolocumab","volume":"377","author":"Giugliano","year":"2017","journal-title":"N Engl J Med."},{"key":"R29-20261002","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"key":"R30-20261002","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/jama.2022.5218","article-title":"Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial","volume":"327","author":"R\u00e4ber","year":"2022","journal-title":"JAMA"},{"key":"R31-20261002","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.jcmg.2022.03.002","article-title":"Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction","volume":"15","author":"Nicholls","year":"2022","journal-title":"JACC Cardiovasc Imaging."},{"key":"R32-20261002","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1161\/CIRCULATIONAHA.123.066213","article-title":"Inflammation and cholesterol as predictors of cardiovascular events among 13 970 contemporary high-risk patients with statin intolerance","volume":"149","author":"Ridker","year":"2024","journal-title":"Circulation"},{"key":"R33-20261002","doi-asserted-by":"crossref","first-page":"107238","DOI":"10.1016\/j.vph.2023.107238","article-title":"Targeting residual inflammatory risk: the next frontier for atherosclerosis treatment and prevention","volume":"153","author":"Ridker","year":"2023","journal-title":"Vascul Pharmacol."},{"key":"R34-20261002","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-Reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med."},{"key":"R35-20261002","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1161\/01.CIR.0000029743.68247.31","article-title":"Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction","volume":"106","author":"Plenge","year":"2002","journal-title":"Circulation"},{"key":"R36-20261002","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jacl.2026.02.003","article-title":"Beyond lipid lowering: effects of PCSK9 inhibition on inflammation and HDL function","volume":"20","author":"Seidel","year":"2026","journal-title":"J Clin Lipidol."},{"key":"R37-20261002","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1161\/CIRCULATIONAHA.124.072756","article-title":"Intensive lowering of LDL cholesterol levels with evolocumab in autoimmune or inflammatory diseases: an analysis of the FOURIER trial","volume":"151","author":"Zimerman","year":"2025","journal-title":"Circulation"},{"key":"R38-20261002","doi-asserted-by":"crossref","first-page":"117180","DOI":"10.1016\/j.atherosclerosis.2023.06.971","article-title":"Evidence of an anti-inflammatory effect of PCSK9 inhibitors within the human atherosclerotic plaque","volume":"378","author":"Marfella","year":"2023","journal-title":"Atherosclerosis"},{"key":"R39-20261002","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jacbts.2025.03.010","article-title":"Impact of in-hospital PCSK9 inhibition on myocardial inflammation after myocardial infarction: a randomized clinical trial","volume":"10","author":"Ziogos","year":"2025","journal-title":"JACC Basic Transl Sci."},{"key":"R40-20261002","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1016\/j.jacc.2019.08.010","article-title":"Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS)","volume":"74","author":"Koskinas","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"R41-20261002","doi-asserted-by":"crossref","first-page":"e023328","DOI":"10.1161\/JAHA.121.023328","article-title":"Effects of PCSK9 targeting: alleviating oxidation, inflammation, and atherosclerosis","volume":"11","author":"Punch","year":"2022","journal-title":"J Am Heart Assoc."},{"key":"R42-20261002","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1161\/CIRCULATIONAHA.118.034309","article-title":"Clinical benefit of evolocumab by severity and extent of coronary artery disease: analysis from FOURIER","volume":"138","author":"Sabatine","year":"2018","journal-title":"Circulation"},{"key":"R43-20261002","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J Am Coll Cardiol."},{"key":"R44-20261002","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1161\/CIRCULATIONAHA.120.046524","article-title":"Peripheral artery disease and venous thromboembolic events after acute coronary syndrome: role of lipoprotein(a) and modification by alirocumab: prespecified analysis of the ODYSSEY OUTCOMES randomized clinical trial","volume":"141","author":"Schwartz","year":"2020","journal-title":"Circulation"},{"key":"R45-20261002","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","article-title":"Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk)","volume":"137","author":"Bonaca","year":"2018","journal-title":"Circulation"},{"key":"R46-20261002","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1016\/j.jacc.2025.10.036","article-title":"Obesity-associated cardiovascular risk and benefit from PCSK9 inhibition: a prespecified analysis from FOURIER","volume":"87","author":"Kang","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"R47-20261002","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1161\/CIRCULATIONAHA.125.077549","article-title":"Efficacy and safety of very low achieved LDL-cholesterol in patients with prior ischemic stroke","volume":"153","author":"Monguillon","year":"2026","journal-title":"Circulation"},{"key":"R48-20261002","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jacc.2025.04.049","article-title":"Safety and lipid-lowering efficacy of inclisiran monotherapy in patients without ASCVD: the VICTORION-mono randomized clinical trial","volume":"86","author":"Taub","year":"2025","journal-title":"J Am Coll Cardiol."},{"key":"R49-20261002","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1016\/j.jacl.2025.04.157","article-title":"LDL-C management with inclisiran plus usual care vs usual care alone in participants with recent acute coronary syndrome: victorion-inception","volume":"19","author":"Knowlton","year":"2025","journal-title":"J Clin Lipidol."},{"key":"R50-20261002","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ahj.2025.05.014","article-title":"Design and rationale of the VICTORION-difference study: a phase 4 randomized, double-blind, placebo-controlled clinical trial to assess inclisiran's early efficacy, safety, tolerability, as well as its impact on quality of life in individuals with hypercholesterolemia","volume":"289","author":"Landmesser","year":"2025","journal-title":"Am Heart J."},{"key":"R51-20261002","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ahj.2025.08.001","article-title":"Design and rationale of a randomized clinical trial assessing the effect of inclisiran on atherosclerotic plaque in individuals without previous cardiovascular event and without flow- limiting lesions identified in an in-hospital screening: the VICTORION-PLAQUE primary prevention trial","volume":"291","author":"Revaiah","year":"2026","journal-title":"Am Heart J."},{"key":"R53-20261002","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11883-024-01199-2","article-title":"Oral PCSK9 inhibitors","volume":"26","author":"Agarwala","year":"2024","journal-title":"Curr Atheroscler Rep."},{"key":"R54-20261002","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.jacc.2023.02.018","article-title":"Phase 2b randomized trial of the oral PCSK9 inhibitor MK-0616","volume":"81","author":"Ballantyne","year":"2023","journal-title":"J Am Coll Cardiol."},{"key":"R55-20261002","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1001\/jama.2025.20620","article-title":"Efficacy and safety of oral PCSK9 inhibitor enlicitide in adults with heterozygous familial hypercholesterolemia: a randomized clinical trial","volume":"335","author":"Ballantyne","year":"2026","journal-title":"JAMA"},{"key":"R56-20261002","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1177\/2047487320902750","article-title":"LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER trial","volume":"28","author":"Sever","year":"2021","journal-title":"Eur J Prev Cardiol."},{"key":"R57-20261002","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.3390\/jcm14134469","article-title":"PCSK9-targeting drugs and gender: are there any differences?","volume":"14","author":"Liberati","year":"2025","journal-title":"J Clin Med."},{"key":"R58-20261002","doi-asserted-by":"crossref","first-page":"117108","DOI":"10.1016\/j.atherosclerosis.2023.03.013","article-title":"Sex differences in efficacy and safety of PCSK9 monoclonal antibodies: a real-world registry","volume":"384","author":"Galema-Boers","year":"2023","journal-title":"Atherosclerosis"},{"key":"R59-20261002","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jacl.2022.12.002","article-title":"Sex differences in LDL-C response to PCSK9 inhibitors: a real world experience","volume":"17","author":"Paquette","year":"2023","journal-title":"J Clin Lipidol."},{"key":"R60-20261002","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/FJC.0000000000001205","article-title":"Sex differences in low-density lipoprotein cholesterol reduction with PCSK9 inhibitors in real-world patients: the LIPID-REAL registry","volume":"79","author":"Cordero","year":"2022","journal-title":"J Cardiovasc Pharmacol."},{"key":"R61-20261002","doi-asserted-by":"crossref","first-page":"e009221","DOI":"10.1161\/JAHA.118.009221","article-title":"Lower on-treatment low-density lipoprotein cholesterol and major adverse cardiovascular events in women and men: pooled analysis of 10 ODYSSEY phase 3 alirocumab trials","volume":"7","author":"Vallejo-Vaz","year":"2018","journal-title":"J Am Heart Assoc."},{"key":"R62-20261002","doi-asserted-by":"crossref","first-page":"101022","DOI":"10.1016\/j.ajpc.2025.101022","article-title":"Sex differences in the treatment with PCSK9 monoclonal antibodies-real world experience from a dedicated preventive cardiology clinic","volume":"23","author":"Hodeda","year":"2025","journal-title":"Am J Prev Cardiol."},{"key":"R63-20261002","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.atherosclerosis.2020.07.014","article-title":"Sex-specific predictors of PCSK9 levels in a European population: the IMPROVE study","volume":"309","author":"Ferri","year":"2020","journal-title":"Atherosclerosis"},{"key":"R64-20261002","doi-asserted-by":"crossref","first-page":"953845","DOI":"10.3389\/fphar.2022.953845","article-title":"Sex difference in circulating PCSK9 and its clinical implications","volume":"13","author":"Jia","year":"2022","journal-title":"Front Pharmacol."},{"key":"R65-20261002","doi-asserted-by":"crossref","first-page":"e548","DOI":"10.1016\/j.jacl.2024.04.122","article-title":"Alirocumab and cardiovascular outcomes according to sex and lipoprotein(a) after acute coronary syndrome: a report from the ODYSSEY OUTCOMES study","volume":"18","author":"Bittner","year":"2024","journal-title":"J Clin Lipidol."},{"key":"R66-20261002","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.jacl.2021.08.001","article-title":"Race\/ethnic and sex differences in the initiation of Non-statin lipid-lowering medication following myocardial infarction","volume":"15","author":"Colvin","year":"2021","journal-title":"J Clin Lipidol."},{"key":"R67-20261002","doi-asserted-by":"crossref","first-page":"e019331","DOI":"10.1161\/JAHA.120.019331","article-title":"Adoption of PCSK9 inhibitors among patients with atherosclerotic disease","volume":"10","author":"Dayoub","year":"2021","journal-title":"J Am Heart Assoc."},{"key":"R68-20261002","doi-asserted-by":"crossref","first-page":"e019254","DOI":"10.1161\/JAHA.120.019254","article-title":"Factors associated with PCSK9 inhibitor initiation among US veterans","volume":"10","author":"Derington","year":"2021","journal-title":"J Am Heart Assoc."},{"key":"R69-20261002","doi-asserted-by":"crossref","first-page":"e016839","DOI":"10.1161\/JAHA.120.016839","article-title":"Effects of evolocumab on low-density lipoprotein cholesterol, non-high density lipoprotein cholesterol, apolipoprotein B, and lipoprotein(a) by race and ethnicity: a meta-analysis of individual participant data from double-blind and open-label extension studies","volume":"10","author":"Daviglus","year":"2021","journal-title":"J Am Heart Assoc."},{"key":"R70-20261002","doi-asserted-by":"crossref","first-page":"e007237","DOI":"10.1161\/CIRCOUTCOMES.120.007237","article-title":"Predictors of PCSK9 (proprotein convertase Subtilisin\/Kexin type 9) inhibitor prescriptions for secondary prevention of clinical atherosclerotic cardiovascular disease","volume":"14","author":"Blumenthal","year":"2021","journal-title":"Circ Cardiovasc Qual Outcomes."},{"key":"R71-20261002","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jacc.2024.11.019","article-title":"Long-term lipid lowering with evolocumab in older individuals","volume":"85","author":"Al Said","year":"2025","journal-title":"J Am Coll Cardiol."},{"key":"R72-20261002","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1161\/CIRCULATIONAHA.125.077603","article-title":"Cardiac allograft vasculopathy inhibition with alirocumab: the CAVIAR trial","volume":"153","author":"Fearon","year":"2026","journal-title":"Circulation"},{"key":"R73-20261002","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1016\/j.jacc.2017.10.001","article-title":"PCSK9 inhibitors: economics and policy","volume":"70","author":"Hlatky","year":"2017","journal-title":"J Am Coll Cardiol."},{"key":"R74-20261002","doi-asserted-by":"crossref","first-page":"221","DOI":"10.7326\/M18-1776","article-title":"Cost-effectiveness of alirocumab: a just-in-time analysis based on the ODYSSEY outcomes trial","volume":"170","author":"Kazi","year":"2019","journal-title":"Ann Intern Med."},{"key":"R75-20261002","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1016\/j.jacc.2020.03.029","article-title":"Cost-effectiveness of alirocumab in patients with acute coronary syndromes: the ODYSSEY OUTCOMES trial","volume":"75","author":"Bhatt","year":"2020","journal-title":"J Am Coll Cardiol."}],"container-title":["Journal of Cardiovascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FJC.0000000000001852","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:00:55Z","timestamp":1790949655000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/FJC.0000000000001852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":72,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/fjc.0000000000001852","relation":{},"ISSN":["1533-4023","0160-2446"],"issn-type":[{"value":"1533-4023","type":"electronic"},{"value":"0160-2446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"2026-04-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}